A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
Abbott's MDx sales were driven by continued strong growth in its infectious disease testing business but were partly offset by the planned scale down of its genetics business.
The release clarifies issues related to the timing of revenue recognition for transactions outside the US.
The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.
Prequalification now enables procurement in numerous countries within sub-Saharan Africa that have regulations requiring this type of oversight.
The prototype showed biases at low virus concentrations and the researchers raised concerns over use of whole blood versus plasma HIV RNA as a biomarker.
Following a partial response to Abbott's request to audit its books, Alere said it is confident the transaction will be completed.
The GenomeWeb Index fell 1 percent in April, outperforming the Nasdaq, but falling significantly short of the performance of the Nasdaq Biotech Index.
Alere also said that some of its creditors have agreed to waive defaults arising from its delay in filing its 2015 earnings report, though others have already filed default notices.
The company said its financial plan contemplates the acquisition of both St. Jude and Alere, which is under investigation for its foreign business practices.
A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.
A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.
Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.